Topical corticosteroid withdrawal (‘steroid addiction’): an update of a systematic review

References

• Mehta AB, Nadkarni NJ, Patil SP, et al. Topical corticosteroids in dermatology. Indian J Dermatol Venereol Leprol. 2016;82(4):371–378.
   PubMed Web of Science ®Google Scholar
• Maroti M, Ulff E, Wijma B. Quality of life before and 6 weeks after treatment in a dermatological outpatient treatment unit. J Eur Acad Dermatol Venereol. 2006;20(9):1081–1085.
   PubMed Web of Science ®Google Scholar
• Borghi A, Odorici G, Scuderi V, et al. Measuring perceived benefit and disease-related burden in patients affected with vulvar lichen sclerosus after a standard topical corticosteroid treatment. Results from a cohort study using Pictorial Representation of Illness and Self-Measure and Dermatology Life Quality Index. Dermatologic Therapy. 2020;33(6):e14334.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Jaworski JC, Kaiser JD, et al. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;16(1):75.
   PubMed Web of Science ®Google Scholar
• Samarasekera EJ, Sawyer L, Wonderling D, et al. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. Br J Dermatol. 2013;168(5):954–967.
   PubMed Web of Science ®Google Scholar
• Hajar T, Leshem YA, Hanifin JM, et al. A systematic review of topical corticosteroid withdrawal (“steroid addiction”) in patients with atopic dermatitis and other dermatoses. J Am Acad Dermatol. 2015;72(3):541–549.
   PubMed Web of Science ®Google Scholar
• Li AW, Yin ES, Antaya RJ. Topical corticosteroid phobia in atopic dermatitis: a systematic review. JAMA Dermatol. 2017;153(10):1036–1042.
   PubMed Web of Science ®Google Scholar
• Howick J, Chalmers I, Glasziou P, et al. Explanation of the 2011 Oxford Centre for Evidence-Based Medicine (OCEBM) levels of evidence (background document) [Internet]. Oxford (UK): Oxford Centre for Evidence-Based Medicine; 2020 [cited 2020 July 31]. https://www.cebm.net/index.aspx?o=5653
   Google Scholar
• Howick J, Chalmers I, Glasziou P, et al. The Oxford 2011 Levels of Evidence[Internet]. Oxford (UK): Oxford Centre for Evidence-Based Medicine; 2020 [cited 2020 July 31]. http://www.cebm.net/index.aspx?o=5653
   Google Scholar
• Murad MH, Sultan S, Haffar S, et al. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60–63.
   PubMedGoogle Scholar
• Moola S, Munn Z, Tufanaru C, et al. Systematic reviews of etiology and risk. In: Aromataris E, Munn Z, editors. JBI manual for evidence synthesis. Adelaide (Australia): JBI; 2020.
   Google Scholar
• Jain S, Mohapatra L, Mohanty P, et al. Study of clinical profile of patients presenting with topical steroid-induced facial dermatosis to a tertiary care hospital. Indian Dermatol Online J. 2020;11(2):208–211.
   PubMedGoogle Scholar
• Sheary B. Steroid withdrawal effects following long-term topical corticosteroid use. Dermatitis. 2018;29(4):213–218.
   PubMed Web of Science ®Google Scholar
• Bender B, Prestia A, Lynfield Y. The headlight sign in neurodermatitis. Cutis. 1969;5:1406–1408.
   Google Scholar
• Sheary B. Topical steroid withdrawal: a case series of 10 children. Acta Derm Venereol. 2019;99(6):551–556.
   PubMed Web of Science ®Google Scholar
• Seok J, Choi SY, Li K, et al. Recalcitrant steroid-induced rosacea successfully treated with 0.03% tacrolimus and 595-nm pulsed dye laser. Eur J Dermatol. 2016;26(3):312–314.
   PubMed Web of Science ®Google Scholar
• Zhang B, Pan F, Zhu K. Bilateral Morganella Morganii keratitis in a patient with facial topical corticosteroid-induced rosacea-like dermatitis: a case report. BMC Ophthalmol. 2017;17(1):106.
   PubMed Web of Science ®Google Scholar
• Sheary B. Topical corticosteroid addiction and withdrawal in a 6 year old. J Prim Health Care. 2017;9(1):90–93.
   PubMed Web of Science ®Google Scholar
• Tatu AL. Topical steroid induced facial rosaceiform dermatitis. Acta Endocrinol. 2016;12(2):232–233.
   Google Scholar
• Hodge BD, Huynh TN, Brodell RT. “Folly” à deux: topical corticosteroid addiction in mother and son. JAAD Case Rep. 2019;5(1):82–85.
   PubMedGoogle Scholar
• Dhossche J, Simpson E, Hajar T. Topical corticosteroid withdrawal in a pediatric patient. JAAD Case Rep. 2017;3(5):420–421.
   PubMedGoogle Scholar
• Arnold KA, Treister AD, Lio PA. Dupilumab in the management of topical corticosteroid withdrawal in atopic dermatitis: a retrospective case series. JAAD Case Rep. 2018;4(9):860–862.
   PubMedGoogle Scholar
• Jakhar D, Kaur I, Misri R. Topical 10% Tranexamic acid for erythematotelangiectatic steriod induced rosacea. J Am Acad Dermatol. 2020.
   Web of Science ®Google Scholar
• Gust P, Jacob SE. The role of delayed-delayed corticosteroid contact dermatitis in topical steroid withdrawal. J Am Acad Dermatol. 2016;75(4):e167.
   PubMed Web of Science ®Google Scholar
• Doss N. Topical corticosteroid abuse: Africa perspective. In: Lahiri K, editor. A treatise on topical corticosteroids in dermatology: use, misuse and abuse. Singapore (Singapore): Springer; 2018. p. 229–235.
   Google Scholar
• Handog EB, Enriquez-Macarayo MJ. Topical corticosteroid abuse: Southeast Asia perspective. In: Lahiri K, editor. A treatise on topical corticosteroids in dermatology: use, misuse and abuse. Singapore (Singapore): Springer; 2018. p. 209–222.
   Google Scholar
• Peltzer K, Pengpid S. Knowledge about, attitude toward, and practice of skin lightening products use and its social correlates among university students in five Association of Southeast Asian Nations (ASEAN) countries. Int J Dermatol. 2017;56(3):277–283.
   PubMed Web of Science ®Google Scholar
• Song SY, Jung SY, Kim E. Steroid phobia among general users of topical steroids: a cross-sectional nationwide survey. J Dermatolog Treat. 2019;30(3):245–250.
   PubMed Web of Science ®Google Scholar